Data-Backed
Efficacy & Safety
Designed for Real-World
Animal Care
Manufacturing
Standards
Product Overview
Ethiqa XR is an extended-release buprenorphine suspension designed specifically for animal care. With FDA-indexing and a well-documented safety profile across captive rodents, laboratory rabbits, ferrets, and non-human primates.
Manufactured under strict cGMP and DEA standards, it is trusted by over 600 veterinary institutions nationwide. Supported by peer-reviewed research, it delivers consistent, reliable results for busy veterinary professionals nationwide.
Supported by Veterinary Experts Nationwide
FDA-Indexed for Veterinary Use
Backed by Peer-Reviewed Research
Manufactured to cGMP & DEA Standards
5
5 Years of proven Buprenorphine
Pain Management
600 +
Serving 600+
Institutions Nationwide
72 hrs
Up to 72 Hours of
Continuous Pain Relief
Innovative Pain Relief for Veterinary Professionals
Our science-backed extended-release formulation helps enhance animal welfare and consistent results due to less injections supporting post-procedural pain relief in multi-species (captive rodents, ferrets, laboratory rabbits, and non-human primates). Designed for real-world use. It empowers veterinarians with regulatory compliance, and long-lasting relief for up to 72-hours.
- Addressing Unmet Clinical Needs in Animal Health
- Supporting Evidence-Based Veterinary Practice
- Enhancing Animal Welfare Through Innovation
- Empowering Vets With Reliable, Compliant Solutions
What Sets Ethiqa XR Apart
Created to solve clinical and logistical challenges, by offering a safer administration with less injections which helps obtain consistent results. It helps improve continuity of care, and reduces handling stress for animals and staff.
- Minimizes need for repeat dosing
- Enhances continuity of care
- Reduces handling stress for animals and teams
Built for Veterinary Confidence
Ethiqa XR is FDA-indexed, giving veterinarians peace of mind that Ethiqa XR is an extended-release buprenorphine product that meets the FDA regulations and can be used for office stock. Every dose is backed by consistent quality, compliance, and care.
That means you can count on Ethiqa XR for reliable performance, regulatory assurance, and the support you need to treat animals safely and effectively, every time.
Safety & Efficacy
Ethiqa XR, the only FDA-indexed, extended-release buprenorphine indicated for control of post-procedure pain in captive rodents, ferrets, laboratory rabbits, and non-human primates.
- Up to 72‑Hour Pain Relief from a Single Dose
- Demonstrated Safety in Multiple Species
- No Impact on Vital Organ Health or Behavior
- Pharmacokinetic Data Confirm Sustained Analgesia
- Peer‑Reviewed & FDA‑Reviewed Research Backing
Up to 72-Hour Pain Relief from a Single Dose
A single injection of Ethiqa XR provides up to 72 hours of reliable pain relief allowing minimized stress for both animals and caregivers. Supported by years of peer-reviewed research, it’s trusted by veterinarians to deliver consistent, long-lasting comfort.
- Provides up to 72 hours of continuous pain relief
- Backed by years of peer-reviewed research
- Used successfully in thousands of cases
What the data confirms is what veterinarians see every day: Ethiqa XR is a safe, well-tolerated product that eases handling while ensuring effective pain management.
- Up to 72‑Hour Pain Relief from a Single Dose
- Demonstrated Safety in Multiple Species
- No Impact on Vital Organ Health or Behavior
- Pharmacokinetic Data Confirm Sustained Analgesia
- Peer‑Reviewed & FDA‑Reviewed Research Backing
Demonstrated Safety in Multiple Species
Ethiqa XR has been studied extensively across research models, consistently showing a strong safety profile with no significant adverse effects.
- Demonstrated safety in multiple species
- Backed by rigorous clinical trials
- Proven across thousands of research applications
These findings reflect real-world experience: veterinarians can count on Ethiqa XR as a dependable, well-tolerated solution for long-term pain management.
- Up to 72‑Hour Pain Relief from a Single Dose
- Demonstrated Safety in Multiple Species
- No Impact on Vital Organ Health or Behavior
- Pharmacokinetic Data Confirm Sustained Analgesia
- Peer‑Reviewed & FDA‑Reviewed Research Backing
No Impact on Vital Organ Health or Behavior
Comprehensive evaluations confirm Ethiqa XR does not interfere with vital organ health, physiological stability, or normal animal behavior.
- No adverse impact on liver, kidney, or cardiac health
- Normal behavior maintained throughout studies
- Safe profile confirmed across species
This science echoes clinical experience: Ethiqa XR supports recovery without disrupting overall health or natural behavior.
- Up to 72‑Hour Pain Relief from a Single Dose
- Demonstrated Safety in Multiple Species
- No Impact on Vital Organ Health or Behavior
- Pharmacokinetic Data Confirm Sustained Analgesia
- Peer‑Reviewed & FDA‑Reviewed Research Backing
Pharmacokinetic Data Confirm Sustained Analgesia
Pharmacokinetic studies validate that Ethiqa XR provides steady, predictable pain relief for up to 72 hours after a single dose.
- Pharmacokinetics confirm reliable analgesia
- Consistent therapeutic levels maintained
- Efficacy verified through validated models
Veterinarians see in practice what the data proves: Ethiqa XR delivers safe, sustained pain relief with each treatment.
- Up to 72‑Hour Pain Relief from a Single Dose
- Demonstrated Safety in Multiple Species
- No Impact on Vital Organ Health or Behavior
- Pharmacokinetic Data Confirm Sustained Analgesia
- Peer‑Reviewed & FDA‑Reviewed Research Backing
Peer‑Reviewed & FDA‑Reviewed Research Backing
Ethiqa XR is supported by both independent peer-reviewed studies and FDA review, ensuring confidence backed by science and regulation.
- Backed by peer-reviewed publications
- Reviewed and approved by the FDA
- Supported by extensive clinical evidence
What veterinarians observe daily is reinforced by data and oversight: Ethiqa XR is a trusted, validated solution for safe and effective pain management.
Care Across Species
Ethiqa XR, the only FDA-indexed, extended-release buprenorphine indicated for control of post-procedure pain in captive rodents, ferrets, laboratory rabbits, and non-human primates.
- Captive Rodents
- Ferrets
- Rabbits
- Non-Human Primates
Consistent Pain Relief for Rodents
Ethiqa XR is FDA-approved for post-procedural pain in rodents like mice and rats. One injection provides up to 72 hours of steady relief. The less handling reduces the stress of the animals which helps result in consistent results. Safety studies confirm it’s well tolerated, making it ideal for humane care in research.
Extended Comfort for Ferrets
For ferrets, Ethiqa XR provides effective pain relief after surgery. It reaches therapeutic blood levels quickly and maintains them for up to 72 hours. This sustained relief supports smoother, less stressful recoveries, improving comfort and welfare in research settings.
Reliable Analgesia for Rabbits
Ethiqa XR delivers consistent, long-lasting pain relief for rabbits with a single injection lasting up to 72 hours. Its strong safety profile makes it a trusted option, supporting humane, effective pain management during research procedures involving laboratory rabbits.
Safe Relief for Primates
Ethiqa XR offers extended pain control in non-human primates with a single injection. It maintains therapeutic blood levels for up to 72 hours. Studies report no adverse effects or abnormal behaviors, supporting its safe, reliable use in primate research care.
FAQ
We’ve answered some of the most common questions about Ethiqa XR’s use, safety, and support.
See All FAQsThe NDC number is 86084-100-30.
Ethiqa XR is packaged in a 5 mL glass vial containing 3.0 mL injectable drug suspension.
- Be sure to weigh each animal to calculate an accurate dose. For example, the dose for a 20-gram mouse would be a single subcutaneous injection of 0.05 mL (3.25 mg/kg body weight)
- If needed, a single dose can be repeated if needed after 72 hours in all animals.
Ethiqa XR currently has a 36-month expiration date from the date of manufacture. The expiration date is indicated on both the vial label and carton.
For questions regarding expiration, please contact Fidelis Animal Health, Inc at 833-ETHIQAXR (833-384-4729).
Ethiqa XR is currently available through:
- MWI Animal Health (phone 800.824.3703, mwiah.com)
- Covetrus (phone 855-724-3461, northamerica.covetrus.com)
- Midwest Veterinary Supply (phone 800-MIDWEST, midwestvetsupply.com)
- Patterson Veterinary (phone 800.225.7911, pattersonvet.com)
- Hanna’s Pharmaceutical Supply (phone 302.571.8761, hannapharm.com).
Ethiqa XR can be ordered by a licensed veterinarian or lab technician. If ordered by a lab technician, the use of the drug must be overseen by a licensed vet. Please visit EthiqaXR.com/ordering/ for more information.
If you have any questions or need assistance ordering product, please contact us at info@fidelisah.com
We’re Here to Support You
Your insights matter—because animal care starts with true collaboration. Ethiqa XR is a trusted, science-backed product for the control of post-procedural pain in captive rodents, ferrets, laboratory rabbits, and non-human primates. We are here to support you every step of the way. Connect with our team, ask questions, and stay informed. Together, we’re advancing animal welfare and raising the standard of care.
Learn More
Real peopleproviding dedicated support
Direct access to experienced veterinary experts
Backed by rigorous, proven research data.
ETH.LP.205.01.D.ALL.AL
Boxed Warning
Abuse Potential
ETHIQA XR contains buprenorphine, an opioid that exposes humans to risks of misuse, abuse, and addiction, which can lead to overdose and death. Use of buprenorphine may lead to physical dependence. The risk of abuse by humans should be considered when storing, administering, and disposing of ETHIQA XR. Persons at increased risk for opioid abuse include those with a personal or family history of substance abuse (including drugs or alcohol) or mental illness (e.g., depression).
Life-Threatening Respiratory Depression
Serious, life-threatening, or fatal respiratory depression may occur with accidental exposure to or with misuse or abuse of ETHIQA XR. Monitor for respiratory depression if human exposure to buprenorphine occurs. Misuse or abuse of buprenorphine by swallowing, snorting, or injecting poses a significant risk of overdose and death.
Accidental Exposure
Because of the potential for adverse reactions associated with accidental exposure, ETHIQA XR should only be administered by veterinarians, veterinary technicians, or laboratory staff who are trained in the handling of potent opioids. Accidental exposure to ETHIQA XR, especially in children, can result in a fatal overdose of buprenorphine.
Risks From Concurrent Misuse or Abuse with Benzodiazepines or Other CNS Depressants
Concurrent misuse or abuse of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.
See HUMAN SAFETY WARNINGS for detailed information.
Important Safety Information
For Captive Rodents, Ferrets, Laboratory Rabbits, and Non-Human Primates:
Only administer Ethiqa XR® by subcutaneous injection. Ethiqa XR is not intended for intravenous, intra-arterial, intrathecal, intramuscular, or intra-peritoneal injection. Do not use in animals with pre-existing respiratory compromise.
Death has been reported when non-steroidal anti-inflammatory drugs (NSAIDs such as meloxicam and carprofen) and Ethiqa XR have been administered concomitantly in mice.
Do not house rats on wood chip-type bedding after administration of Ethiqa XR. Pica involving wood chip type bedding can be lethal.
Ethiqa XR may cause sedation, decreased blood pressure, decreased heart rate, decreased gastrointestinal mobility, and respiratory depression. Use caution with concomitant administration of Ethiqa XR with drugs that cause respiratory depression. Animals should be monitored for signs of decreased cardiovascular and respiratory function when receiving Ethiqa XR.
The safety of Ethiqa XR has not been evaluated in pregnant, lactating, neonatal, or immune-compromised animals.
For Humans:
Not for use in humans. Keep out of reach of children and pets.
Ethiqa XR contains buprenorphine, a Schedule III controlled substance with an abuse potential similar to other Schedule III opioids, which may lead to overdose and death.
Ethiqa XR should be handled appropriately to minimize the risk of misuse, abuse, addiction, and criminal diversion, including restriction of access, the use of accounting procedures, and proper disposal methods as appropriate to the laboratory setting and as required by law.
Ethiqa XR should only be handled and administered by a veterinarian, veterinarian technician, or laboratory staff trained in the handling of potent opioids. Wear protective clothing when administering Ethiqa XR to avoid direct contact with human skin, eyes, oral, or other mucus membranes which could result in absorption of buprenorphine and adverse reactions.
For more information, consult the Prescribing Information including the Boxed Warning.
SA.EthiqaXR.060.05.2024